ARROWHEAD PHARMACEUTICALS, INC. Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest (Deprecated 2013-01-31)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest (Deprecated 2013-01-31) of $254.28 thousand for the 12-month period ending 2011-09-30, per its 10-K filed 2013-12-18.
Discontinued › Notes
us-gaap:MinorityInterestIncreaseFromStockIssuance · last filed 2013-12-18
- ARROWHEAD PHARMACEUTICALS, INC. noncontrolling interest, increase from equity issuance or sale of parent equity interest (deprecated 2013-01-31) for fiscal 2011 was $254.28K, a 15.24% decline from fiscal 2010.
- ARROWHEAD PHARMACEUTICALS, INC. noncontrolling interest, increase from equity issuance or sale of parent equity interest (deprecated 2013-01-31) for fiscal 2010 was $300.00K.
| Period end | Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest (Deprecated 2013-01-31) 12 month |
|---|---|
| 2011-09-30 | $254.28K 10-K · filed 2013-12-18 |
| 2010-09-30 | $300.00K 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |